NCT05488405View on ClinicalTrials.gov

Mesalazine Oral Suspension in Active Eosinophilic Esophagitis

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

February 9, 2023

Primary Completion Date

June 30, 2023

Study Completion Date

July 20, 2023

Conditions
Eosinophilic Esophagitis
Interventions
DRUG

Mesalamine Oral Product

Mesalamine oral suspension for oral use

Trial Locations (1)

8091

Universitätsspital Zürich, Zurich

Sponsors
All Listed Sponsors
lead

Dr. Falk Pharma GmbH

INDUSTRY

NCT05488405 - Mesalazine Oral Suspension in Active Eosinophilic Esophagitis | Biotech Hunter | Biotech Hunter